Chief Scientific Officer responsible for pre-clinical studies, formulation development and company’s pipeline.
Prior to working at NeuroSense, Oron was CSO at NeuroDerm, responsible for the development of their unique formulation (acquired by Mitsubishi Tanabe for $1.1 billion).
In the past, she also served as Chief Science Officer at Harlan Biotech Israel Ltd., and R&D team leader at Insight Biopharmaceuticals Ltd.
Dr. Yacoby-Zeevi has 20 years of experience in leading research and development programs, and GLP compliant pre-clinical development of numerous small molecule drugs and biologics, in various indications, including CNS diseases.
She is the author of more than 15 patents.
DVM from The Hebrew University of Jerusalem. PhD in Microbiology and Immunology, from Ben-Gurion University